CE Marking Announced for the BD MAX MRSA Assay

BD Diagnostics has announced CE Marking for the BD MAX™ MRSA Assay, for the rapid and accurate identification of methicillin-resistant Staphylococcus aureus (MRSA) in patients. The information provided allows infection control measures to be implemented more quickly, which positively impacts on patient management.

The BD MAX is the first and only fully automated, bench-top molecular system designed to perform a broad range of molecular testing. It has the dual functionality of an open system as well as CE/IVD capabilities. This enables laboratories to consolidate a broad range of molecular tests on a single workstation, providing clinicians with the information that they need to make critical treatment and management decisions.

“When we launched BD MAX earlier this year, our goal was to provide a next-generation molecular testing system designed to accommodate a broad range of assays that laboratories want and need,” said Tom Polen, President, BD Diagnostics – Diagnostic Systems. “As the first healthcare-associated infection assay developed by BD for use on the BD MAX System, this milestone represents further confirmation of the potential of this fully-automated system. This system enables laboratories to offer a broad range of molecular tests that meet both their current and future clinical needs.”

"The challenge to fight healthcare-associated infections in Europe is resulting in an increased number of active surveillance programs for MRSA in a continually resource-constrained environment,” said Hilja Ibert, Vice President and General Manager, BD Diagnostics – Diagnostic Systems in Europe. “The BD MAX MRSA Assay on the BD MAX System provides significant laboratory efficiency and versatility to help address the increasing volume of molecular tests.”

BD has more than 20 assays in the BD MAX System’s pipeline, for a broad range of disease categories. For more information about the BD MAX, visit the BD website by clicking the manufacturer’s website link below.